Neurological Disease

MAP4343 (Standard) is the analytical standard of MAP4343 (HY-107116). This product is intended for research and analytical applications. MAP4343 is the 3-methylether derivative of Pregnenolone. MAP4343 binds in vitro to microtubule-associated protein 2 (MAP2), stimulates the polymerization of tubulin, enhances the extension of neurites and protects neurons against neurotoxic agents.

Imidafenacin (KRP-197; ONO-8025) is an orally active inhibitor of muscarinic (mAChR) M₁ and M₃ receptors. Imidafenacin potently inhibits bladder contraction in vivo and exerts an antidiuretic effect by enhancing the signaling pathway of vasopressin (antidiuretic hormone). Imidafenacin can be used in research related to overactive bladder.

Metaescaline hydrochloride is structurally classified as a phenethylamine.

Azidoindolene 1 is structurally similar to cannabinoid.

CAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with K_i values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively.

Tabersonine hydrochloride is a selective, orally active NLRP3 inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, PI3K/Akt, and p38 MAPK signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer.

Dysiherbaine is an excitatory amino acid. Dysiherbaine is isolated from the marine sponge Lendenfeldia chondrodes. Dysiherbaine activates AMPA and kainate receptors. Dysiherbaine has minor NMDA receptor agonist activity, while it has no effect on L-type voltage-dependent calcium channels. Dysiherbaine induces convulsions and epileptogenic activity in mice. Dysiherbaine is used in epilepsy research.

7-Methyl DMT (7-TMT) is a 5-HT2 receptor agonist. Structurally, 7-Methyl DMT is a tryptamine derivative. It can be used as an analytical reference standard for the psychoactive substance DOM. 7-Methyl DMT is also used in research in the field of neurological diseases.

AUY954 is an oral active and selective sphingosine-1-phosphate receptor 1 agonist with the EC₅₀ values of 1.2 nM, 0.9 nM >10,000 nM, 1,210 nM, >1,000 nM, and 340 nM for hS1P2, mS1P2, S1P2, S1P3, S1P4, and S1P5 receptors, respectively. AUY954 can be used for study of experimental autoimmune neuritis.

Miridesap (Standard) is the analytical standard of Miridesap (HY-101861). This product is intended for research and analytical applications. Miridesap is a ligand for serum amyloid P component (SAP) and intends to inhibit and dissociate SAP binding to amyloid fibrils and tangles.

D-Alanine-d is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC₅₀ of 9 mM for GlyR.

Nelotanserin (Standard) is the analytical standard of Nelotanserin (HY-10559). This product is intended for research and analytical applications. Nelotanserin is a potent 5-HT2A inverse agonist, a moderately potent 5-HT2C partial inverse agonist and a weak 5-HT2B inverse agonist, with IC₅₀s of 1.7, 79, 791 nM in IP accumulation assays, respectively.

SB-699551 (Standard) is the analytical standard of SB-699551 (HY-103100). This product is intended for research and analytical applications. SB-699551 is a potent and selective 5-HT5A antagonist with a K_i value of 5.1 μM. SB-699551 increases the phosphorylation levels of CREB and ATF1, and decreases the phosphorylation levels of AKT, PRAS40, P70S6K, FOXO1, and S6RP. SB-699551 improves drug-induced cognitive deficits. SB-699551 improves social withdrawal and forgetfulness. SB-699551 inhibits breast cancer.

Proglumide (Standard) is the analytical standard of Proglumide. This product is intended for research and analytical applications. Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities.

D-(-)-Quinic acid (Standard) is the analytical standard of D-(-)-Quinic acid. This product is intended for research and analytical applications. D-(-)-Quinic acid scavenges hydrogen peroxide (IC₅₀=87.11 μg/mL) and exhibits antioxidant activity. D-(-)-Quinic acid is the inhibitor for MAO and α-Glucosidase (IC₅₀ =93.75 μg/mL). D-(-)-Quinic acid is orally active.

7-Hydroxycannabidiol (7-OH-CBD) is the metabolite of cannabidiol, which could be found in human serum and saliva.

7'-Methoxy NABUTIE (Compound 23) is a derivative of Aminoalkylindole. 7'-Methoxy NABUTIE can be used in the study of alcohol abuse.

IDT is a safe and effective TNFα and innate immune system modulator. IDT significantly reduced paired helical filament tau and fibrillar amyloid accumulation and increased the infiltrating neutrophil population while reducing TNFα expression in this population. IDT can be used in Alzheimer's disease research.

SKF89976A (hydrochloride) (Standard) is the analytical standard of SKF89976A (hydrochloride) (HY-100228A). This product is intended for research and analytical applications. SKF89976A hydrochloride is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHO cells, respectively.

Alvelestat (Standard) (AZD9668 (Standard)) is the analytical standard of Alvelestat (HY-15651). This product is intended for research and analytical applications. Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis.